The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy.
 
Harriet M. Kluger
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Celldex; ChemoCentryx; Clinigen Group; ElevateBio; ElevateBio; GI Reviewers; Gigagen; Instil Bio; Iovance Biotherapeutics; Merck; Shionogi; Signatera
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
Amod Sarnaik
Honoraria - Medscape; MedStar Health; Physicans' Education Resource
Consulting or Advisory Role - B4CC; Defined Health; Gerson Lehrman Group; Guidepoint Global; Huron Consulting; Iovance Biotherapeutics; Istari; KeyQuest Health
Research Funding - Genentech (Inst); Iovance Biotherapeutics (Inst); Provectus (Inst)
Patents, Royalties, Other Intellectual Property - Compositions and methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy, filed March 20, 2014 U.S. Patent Application No. 61/955,970 and second Application No. 61/973,002 (Inst); Culture of Tumor-infiltrating lymphocytes from tumor digest, filed March 24, 2021 US Patent Application No. 17/279,327 (Inst); Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound, filed August 21, 2018 U.S. Patent Application No. 14/974,357; Rapid method for culture of tumor-infiltrating lymphocytes from core needle biopsies of solid tumors, filed January 2, 2018 U.S. Patent Application No. 62/612,915 (Inst); Tumor-infiltrating lymphocytes and stapled peptoid peptide hybrid peptidomimetics, filed October 11, 2018 U.S. Patent Application No. 16/157,174 (Inst)
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Iovance Biotherapeutics
 
Jason Alan Chesney
Research Funding - Amgen; Bristol-Myers Squibb; Iovance Biotherapeutics; Replimune
Patents, Royalties, Other Intellectual Property - University of Louisville US Patents
 
Karl D. Lewis
Honoraria - Array BioPharma; Iovance Biotherapeutics
Consulting or Advisory Role - Array BioPharma; Iovance Biotherapeutics; Merck; nektar; Regeneron; Roche; Sanofi
Research Funding - alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; Evaxion Biotech; Instil Bio; NexImmune; OncoC4
Honoraria - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Ultimovacs; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Protean Biodiagnostics; Roche; Sellas Life Sciences; Ultimovacs; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Novartis; Roche
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Gino Kim In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis; Sanofi
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Checkmate Pharmaceuticals (Inst); Idera (Inst); Instil Bio (Inst); Regeneron (Inst); Replimune (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Regeneron
 
Patrick Andres Maximilian Terheyden
Honoraria - Bristol-Myers Squibb; CureVac; Merck Serono; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - 4SC; Almirall; Bristol-Myers Squibb; Merck KGaA; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Sylvia Lee
Patents, Royalties, Other Intellectual Property - Patent for BRAF-specific TCR, licensed to Lyell Immunopharma.
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Madan H. Jagasia
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Consulting or Advisory Role - Kadmon
 
Emma Masteller
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Ascendis Pharma; Five Prime Therapeutics; Inovio Pharmaceuticals; Iovance Biotherapeutics; Nurix
 
Rongsu Qi
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Research Funding - Iovance Biotherapeutics
Patents, Royalties, Other Intellectual Property - GRAIL
 
Viktoria Gontcharova
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Gilead Sciences; Iovance Biotherapeutics
Consulting or Advisory Role - Iovance Biotherapeutics; Stanford University
 
Wen Shi
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics; Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Rana Fiaz
Employment - Abbvie; Iovance Biotherapeutics
 
Giri Sulur
Employment - BeiGene; Iovance Biotherapeutics
Stock and Other Ownership Interests - BeiGene; Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Renee Xiao Wu
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Guang Chen
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Sajeve Samuel Thomas
Speakers' Bureau - Amgen; Bms; Genentech; ipsen; Merck; Novartis; Pfizer